PubMed Health⌕ Search

Biomedical subjects

T Meloni

Publications and source records attributed to T Meloni.

At least 109 records · Page 6Linked to original sources
PubMedDate not supplied

Feprazone: absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects.

Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically significant changes of hematologic tests were observed.

Adolescent↗
PubMedDate not supplied

[Concentrations of the IgM and antibodies for the TORCH complex in the umbilical blood (author's transl)].

The Authors have found both IgM and antibodies for the TORCH complex in the umbilical blood of 1500 newborns. In 119 (7.9%) there was an increase of IgM. In 23% of these newborns there were present antibodies for rubella, in 21% antibodies for toxoplasma, in 15.9% antibodies for cytomegalovirus, and in 19.2% antibodies for herpes simplex. However there was no statistical correlation between the antibodies for the TORCH complex and the increase of IgM.

Antibodies↗